HB12 would create a new section of Ohio law governing how drugs are prescribed, dispensed, and administered, including off-label use, and would name the measure the Jeff, Dave, and Angie Patient Right to Try Act. The bill allows a prescriber to issue a prescription for any legal drug, including for off-label use, if the patient or the patient’s personal representative gives informed consent after receiving information about the diagnosis, the drug’s risks and benefits, alternatives, and any financial conflicts of interest. It also requires pharmacists, hospitals, inpatient facilities, and pharmacies to dispense or allow dispensing of such prescriptions unless a narrow religious/moral objection applies or there is a documented life-threatening allergy, contraindication, or interaction.
The bill also addresses hospital and inpatient-facility settings in more detail. It requires facilities to make good-faith efforts to locate unavailable drugs, to allow patients to bring in their own identified medication when appropriate, and to permit a prescriber’s delegate to administer the drug if necessary and allowed by facility standards. It limits when an in-house prescriber’s orders may be modified or discontinued, gives the patient or personal representative the final say in certain disagreements over continuing treatment, and bars facilities from obstructing transfer or discharge when a patient wants to pursue treatment elsewhere. In outpatient settings, it requires disclosure of estimated out-of-pocket costs and an option to pay directly when insurance will not cover a drug or prior authorization would delay treatment.
HB12 would also restrict state regulatory bodies from treating compliant prescribing, dispensing, or administration of drugs under the section as unlawful, unethical, unauthorized, or unprofessional conduct, except in cases of recklessness or gross negligence. It further protects health professionals’ speech by prohibiting discipline or sanctions based on their public or private opinions about the safety, risks, benefits, or efficacy of drugs or medical interventions, so long as the speech itself is not tied to actual patient harm. The bill expressly preserves existing law for controlled substances, REMS drugs, cross-sex hormones and puberty blockers used in violation of current law, abortifacients for known pregnancies, and drugs intended for euthanasia.
The bill’s impact would be to expand patient-directed access to medications, especially off-label uses, while limiting professional discipline and regulatory interference for providers who comply with the bill’s informed-consent framework. It would affect prescribers, pharmacists, hospitals, skilled nursing facilities, rehabilitation facilities, state licensing boards, and the Department of Health by creating new duties to inform, dispense, document, and in some cases accommodate patient requests or transfers. It would also create a new statutory standard that could be used to challenge disciplinary actions or facility policies that conflict with the bill’s requirements.
Because the bill is only introduced and there are no recorded committee transcripts or votes, there is no formal legislative record of support or opposition yet. Based on the text, the measure appears designed to appeal to patient-autonomy and medical-freedom advocates, while likely drawing concern from health care regulators, hospital systems, and professional boards over off-label prescribing, liability, facility workflow, and the bill’s limits on disciplinary authority. The explicit carve-outs for controlled substances, abortion-related drugs, gender-affirming medications, and euthanasia-related drugs suggest the bill also anticipates controversy over politically sensitive areas of medical practice.
HB12 would add section 3792.08 to the Revised Code and create new duties and protections for prescribers, pharmacists, hospitals, skilled nursing facilities, rehabilitation facilities, and state licensing/regulatory agencies. It would require informed consent for prescriptions, including off-label use, mandate dispensing in most cases, limit professional discipline and sanctions for compliant conduct, and protect provider speech about drug safety and efficacy. It would also preserve existing law for controlled substances, REMS drugs, cross-sex hormones/puberty blockers used unlawfully, abortifacients for known pregnancies, and euthanasia-related drugs.
There is no recorded committee testimony or vote history, so the formal legislative sentiment is not yet documented. The bill’s framing as a patient-right-to-try measure and its emphasis on informed consent, access, and provider speech suggest support from advocates of patient autonomy and medical freedom. At the same time, its broad constraints on regulatory oversight and facility discretion imply likely concern from health care institutions, licensing boards, and some clinicians about safety, liability, and operational burdens.
The main points of contention are likely to be the bill’s expansion of off-label prescribing and its requirement that pharmacies and facilities dispense or accommodate drugs despite objections, which could be seen as limiting professional judgment and institutional policies. Another likely dispute is the bill’s restriction on disciplinary action by state boards and agencies, especially the speech protections for providers who express views that differ from regulators or health authorities. The carve-outs for controlled substances, REMS drugs, abortion-related drugs, gender-affirming medications, and euthanasia-related drugs indicate that the bill is also politically sensitive and may draw different reactions depending on the medical context involved.